◆ NeutralVKTXLLYNVO
Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.
The Motley Fool·
Viking Therapeutics raised $575 million through a stock offering and convertible notes to fund multiple phase 3 trials for its obesity drug VK2735 and pipeline development. The company expects to have cash through at least 2028, with key trial results expected between 2027-2028. The company's future depends on VK2735's clinical success.
Read Full Article at The Motley Fool →